Table 1.
Baseline demographics of enrolled patients up (as of 27 February 2019)
| Warfarinn = 48 | Dabigatrann = 49 | P‐value | |
|---|---|---|---|
| Age (years) | 74.5 ± 6.5 | 74.0 ± 5.5 | 0.73 |
| Sex (male) | 27 (56.3%) | 26 (53.1%) | 0.75 |
| Prior myocardial infarction | 8 (16.7%) | 3 (6.1%) | 0.15 |
| History of coronary artery disease | 16 (33.3%) | 8 (16.3%) | 0.08 |
| Prior coronary revascularization | 6 (12.5%) | 1 (2.0%) | 0.03 |
| Prior CABG | 1 (2.1%) | 0 (0%) | 0.24 |
| Heart failure | 7 (14.6%) | 10 (20.4%) | 0.47 |
| Prior ablation | 2 (4.2%) | 5 (10.2%) | 0.32 |
| Pacemaker | 7 (14.6%) | 6 (12.2%) | 0.56 |
| Defibrillator | 2 (4.2%) | 2 (4.1%) | 0.81 |
| Diabetes | 20 (41.7%) | 16 (32.7%) | 0.36 |
| Prior stroke | 5 (10.4%) | 4 (8.2%) | 0.61 |
| Prior transient ischemic attack | 4 (8.3%) | 4 (8.2%) | 0.86 |
| History of depression | 11 (22.9%) | 15 (30.6%) | 0.44 |
| History of peripheral vascular disease | 5 (10.4%) | 3 (6.1%) | 0.37 |
| Chronic obstructive pulmonary disease | 17 (35.4%) | 15 (30.6%) | 0.51 |
| Prior cancer | 13 (27.1%) | 6 (12.2%) | 0.06 |
| Type of AF, n = 64 | 0.74 | ||
| Paroxysmal | 30 (62.5%) | 27 (55.1%) | |
| Persistent | 1 (2.1%) | 3 (6.1%) | |
| Long‐standing persistent | 1 (2.1%) | 2 (4.1%) | |
| BMI (kg/m2), n = 94 | 29.8 ± 6.9 | 30.6 ± 9.9 | 0.66 |
Abbreviations: AF, atrial fibrillation; BMI, body mass index; CABG, Coronary artery bypass grafting.